Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, m rd of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. We have participated in some of the largest cfDNA prospective trials conducted to date. CIRCULATE : A study of molecular-residual-disease-guided treatment in 3,000+ patients with colorectal cancer using the Signatera™ personalized tumor-informed circulating tumor DNA assay SMART: The largest prospective, real-world population study of noninvasive prenatal testing (NIPT) conducted to date, involving 18,000+ pregnancies Trifecta: The largest prospective, fully biopsy-matched cohort study to date evaluating donor-derived cell-free DNA (dd-cfDNA) for kidney transplant recipients We provide clear and detailed test reports to help inform next steps. Signatera™: reports whether circulating tumor DNA (ctDNA) is detected and provides the mean tumor molecular per ML (MTM/mL) for longitudinal assessment Panorama™: reports positive predictive value (PPV) for high risk results, negative predictive value (NPV) for low risk results, and a fetal fraction assessment Prospera™: reports rejection through analysis of donor-derived cfDNA We are committed to reducing the environmental impact of our business. Natera complies with all applicable local, state, and federal environmental regulations and we conduct regular reviews to ensure our supplier partners and contractors do the same. As part of our sustainability and environmental, social, and governance (ESG) program, we are committed to reducing the environmental impact of our laboratories, our corporate offices, our supply chain, and our waste operations.